Portal de Periódicos da CAPES

Treatment with sildenafil citrate in renal transplant patients with erectile dysfunction

2001; Wiley; Volume: 88; Issue: 3 Linguagem: Inglês

10.1046/j.1464-410x.2001.02278.x

1464-410X

R. Castro, F.J. Anglada Curado, J.C. Regueiro López, Marta Vallejo, Jaime Sánchez, Janice Lopez, M.J. Requena Tapia,

Hormonal and reproductive studies

Objective To assess the safety and efficacy of sildenafil citrate in renal transplant patients with erectile dysfunction, as up to half of men with renal failure may be affected and only 60–75% recover potency after transplantation. Patients and methods Fifty patients with erectile dysfunction and a functioning renal transplant were treated using sildenafil (mean age 54 years, mean time on dialysis 35 months, mean time from transplantation 20 months). The hypogastric artery was not used during transplantation in any patient. Sildenafil citrate was prescribed at doses of 25 or 50 mg depending on baseline creatinine values and on the response, and plasma levels of cyclosporin/FK506 were monitored. Results Thirty patients (60%) had a satisfactory response, with a mean time on dialysis of 23 months. Six patients (12%) did not take the sildenafil and in 14 (28%) the drug was ineffective. The mean time on dialysis in this group was 43 months. Six patients (12%) had side‐effects that in no case led to withdrawal of treatment. Plasma levels of cyclosporin/FK506 remained within the safety and efficacy limits in all patients. Conclusions Treatment with sildenafil citrate in renal transplant patients with erectile dysfunction is an effective and safe option, with few side‐effects. Plasma levels of immunosuppressants are unchanged. The response was more effective in patients with a shorter time on dialysis, as penile vascular disease is less advanced.